Gynecologic Research and Cancer Equity: Progress, Process and Future Opportunities

KEMI M. DOLL, MD MSCR

Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Washington School of Medicine University of Hawaii

November 9^{th,} 2024



CONFIDENTIAL – DO NOT DISTRIBUTE

I have no financial conflicts of interest to disclose.



Objectives

1. Introduce The GRACE Center mission, vision, and values.

2. Review GRACE Center research studies.

3. Discuss future horizons and collaboration opportunities.



The GRACE Center

GYNECOLOGIC RESEARCH AND CANCER EQUITY

www.gracecenteruw.com



Kemi Doll, MD MSCR PRINCIPAL INVESTIGATOR (She/Her)



Nadia Khan, MBA ADMINISTRATIVE DIRECTOR (She/Her)

Julianna Alson, MPH Senior project manager (She/Her)



Adrienne Moore, RT, Me-BA DIRECTOR OF PEER SUPPORTERS

(She/Her)



Patrice Williams, B.S



Leah Franklin, MPH

RESEARCH COORDINATOR



Ann Oluloro, MD, MPH gyn onc research fellow

Soledad Jorge, MD MPH ASSISTANT PROFESSOR



Mindy Pike, PhD



PhD Deana Williams, PhD FELLOW MENTORED RESEARCH SCHOLAR



Beza Tadess, MPH RESEARCH COORDINATOR



Maya Gross, MD MPH GYN ONCOLOGY RESEARCH FELLOW



Lisa Johnson PhD

Ms. Bridgette Hempstead Dr. Ronit Katz Tyler Gafney Daisy Ganal Emiko Oshima Dr. Eric Rios-Doria

The GRACE Center

GYNECOLOGIC RESEARCH AND CANCER EQUITY



Nadia Khan, MBA

(She/Her)



Lisa Johnson PhD

Leadership Team

(She/Her)



Research Coordinators





Maya Gross, MD MPH



Ann Oluloro, MD, MPH



Tiffany Jones, MD

Post-Doc / Trainees

The GRACE Center

GYNECOLOGIC RESEARCH AND CANCER EQUITY



Emma DearyDena SalehipourGraduateStudents



Deana Williams, PhD MENTORED RESEARCH SCHOLAR



Soledad Jorge, MD MPH ASSISTANT PROFESSOR

Junior Faculty Mentees



Data Analyst

Mindy Pike, PhD

THE GRACE CENTER: MISSION

The Mission of The GRACE Center is to act to investigate and ameliorate causes of disproportionate suffering from benign and oncologic gynecologic health conditions, so that all people may live full and healthy reproductive lives.

We believe that gynecologic health spans the lifetime and is intimately linked with gynecologic cancers that affect individuals later in life.

Our goal is to unite these perspectives to deepen our understanding of the science of gynecologic cancers through transdisciplinary approaches, grounded in the perspectives of marginalized people with lived experience.

THE GRACE CENTER: WORK

Through our work:

- We seek to create catalytic conversations that deepen awareness and create new connections that facilitate understanding of gynecologic equity issues in the U.S.
- We seek to be a **possibility model** of centering the margins, inclusive leadership, and meaningful impact using research and research partnership as our tools.
- We seek to support the **emergence of more scholars** of gynecologic health equity, through opportunities for students, trainees, staff, and faculty members.

THE GRACE CENTER: VALUES

At the GRACE Center, we value kindness, warm community, high quality work, curiosity, growth and radical innovation.

At the GRACE Center, we acknowledge that we function in racist, sexist, ableist, transphobic, and homophobic systems and we choose to use our work to combat these moral failings to improve the conditions of gynecologic health for marginalized populations.

We value **balance and joy** – and ultimately, believe each one of us can make this world a better place. At the GRACE Center, we give each other grace.

The GRACE Center: 5 Year Vision Intentions (2023)



The GRACE Center: 5 Year Vision Structure



Objectives

1. Introduce The GRACE Center mission, vision, and values.

2. Review GRACE Center research studies.

3. Discuss future horizons and collaboration opportunities.

Endometrial Cancer



66,00 cases/ year

Lifetime risk in US: 3%

1 in 32 women by age 80

5-year survival: 80%

Giaquinto AN et al. *CA Cancer J Clin*, 2022. https://seer.cancer.gov/statfacts/



US Uterine Cancer Statistics by Race/Ethnicity: Mortality





The Black-White mortality gap in endometrial cancer is **one of the largest** in all of cancer care in the US.

Rank	Cancer	Black:White Mortality Rate Ratio
1	Stomach	2.3
2	Multiple Myeloma	2.2
3	Uterine (Endometrial)	2.0 (1.2-2.8)
4	Cervix	1.7
5	Breast	1.4
6	Colorectal	1.3

Giaquinto et al, *CA: A Cancer Journal for Clinicians*, 2022 Clarke et al, *JAMA Oncology*, 2022

US Black women and Endometrial Cancer

• Non-endometroid histology is on the rise for everyone, and most strikingly in Black

Cote et al. Cancer Epi Biom 2015; Clarke et al. JCO 2019

women.

- Mortality rates are the highest among Black women, after adjustment for stage and histology, with 40-60% unexplained.
- Young Black women under 50 are more likely to have high-grade histology (30% non-endometrioid) Mukerjee et al. Gyn Onc 2018
- Black vs. White EC molecular profile differences largely follow known
 differences in histologic subtype
 Wilhite et al. Gyn Onc 2022; Whelan et al. Gyn Onc 2023



Black women's reproductive health



Gynecologic Care Higher rates of

- Fibroids
- Irregular cycles
- Infertility
- Premenopausal Hysterectomy

Obstetrics and Maternal-Fetal Medicine Higher rates of

- Preterm Labor
- Low Birth Weight infants
- Maternal mortality





<u>Gynecologic Cancers</u> Higher mortality in

- Ovarian cancer
- Cervical cancer
- Endometrial cancer

Eichelberger, Doll, Ekpo & Zerden. Black Lives Matter: Claiming a Space for Evidence-Based Outrage in Obstetrics and Gynecology. *AJPH*. Oct 2016.



Disclosure: I have a perspective

"Fundamental Causes" of Social Inequalities in Mortality: A Test of the Theory*

Phelan, Jo C 🔀; Link, Bruce G 🛣; Diez-Roux, Ana 🛣; Kawachi, Ichiro 🛣; Levin, Bruce 🛣. Journal of Health and Social Behavior 45.3 (Sep 2004): 265-85.

Critical Race Theory, Race Equity, and Public Health: Toward Antiracism Praxis

Racial scholars argue that Chandra L. Ford, PhD, and Collins O. Airhihenbuwa, PhD racism produces rates of

Methods for the Scientific Study of Discrimination and Health: An Ecosocial Approach

The scientific study of Nancy Krieger, PhD



ANDHEAIT

THOMAS A. LAVEIST . LYDIA A. ISAAC server

FATAL INVENTION







edited by KAZUKO SUZUKI and DIEGO A. VON VACANO

with preface by HENRY LOUIS GATES, JR

Racism: Science & Tools for the Public Health Professional





Public Health Critical Race Praxis (Ford & Airhehenbuwa)

Racism is **omnipresent in society** and active in the daily lives of people of color.

Racial biases **inform the nature of research questions** and *a priori* assumptions driving research.

Research efforts are EQUITY oriented.

How has knowledge about Black women with EC been constructed? Fundamental Cause Theory (Link & Phelan)

The link between SES and mortality persists over time due to differential access to key flexible resources (knowledge, money, power, prestige, and social connections).

Differences in health outcomes **based on social position in a society** arise in the context of the treatability of a given condition.

What are the modifiable factors that contribute to the Black-White mortality gap in EC? The Ecosocial Theory of Disease Distibution (Krieger)

Embodiment: How we, as humans, 'literally **biologically embody exposures** arising from our societal and ecological context, thereby producing population rates and distribution of disease.'

How does the social environment influence biologic differences in histology and outcomes?

Doll, KM. Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications. *Gynecologic Oncology*. April 2018.

EARLY STUDIES: 2016 - 2020



Endometrial cancer disparities: a race-conscious critique of the literature

Kemi M. Doll, MD, MS; Cyndy R. Snyder, PhD; Chandra L. Ford, PhD, MPH, MLIS



How has knowledge about Black women with EC been constructed?



Race defined as a biological/genetic entity

Observational studies documenting surgical disparities

No work to address repeated

documented treatment inequity

Assumptions that healthcare environments represent 'color-blind' spaces



Absence of the Black woman's voice

Doll KM, Snyder C, Ford CL. AJOG. Sept 2017.



Preliminary work: Cohort Simulation



Data Source: SEER 18-Registry EC Cases 2004 - 2009 Base Population **N= 34,580**

Absolute 5-year mortality gap: $19.3\% \rightarrow 11.6\%$

40% of Black-White mortality gap is attributable to stage at diagnosis and surgery rates

Doll KM, Winn AN, & Goff BA. *AJOG*. March 2017.

Context: Black women's reproductive health



<u>Gynecologic Care</u> Higher rates of

- Fibroids
- Irregular cycles cause abnormal bleeding in young black women





<u>Gynecologic Cancers</u> Results in **normalcy** of abnormal bleeding in older black women

Endometrial cancer

We may have a RACIALIZED view of the primary symptom of endometrial cancer

Robert Wood Johnson Foundation AMFDP 2018 - 2021



Application of The Andersen Model of Total Patient Delay

Appraisal Interval: Normalizing Delay

Community-Engaged Qualitative Study

N=32 Black and White women with EC

Semi-structured interviews (1-2 hours) on experience of menopause, symptom onset, and diagnosis

"I was just surprised. Just surprised. Not alarmed, because it wasn't heavy at all. Very light. But it was there. And I'm like, 'Is that blood?'Because it was nothing compared to what I'd been used to since I was in my 20s. Nothing."

Black women expressed multiple factors associated with delay

- Nature of symptoms: not new, bothersome, painful



- Misattribution of symptoms: fibroids, irregular cycles
- Cue to action: personal waiting period, symptom severity

on, MPH

- Symptom disclosure: misaligned with patient risk

Doll KM, Hempstead BH, Alson JA, Sage L, Lavallee D. JAMA Net Open. May 2020

Appraisal Interval: Overlapping Vulnerability

Overlapping Vulnerability + Underlying Risk

Areas of Vulnerability	Contributor	Black Women Vulnerability
Experiential:	Knowledge about menopause and the menopausal transition.	1
Knowledge	Endometrial Cancer knowledge	1
Experiential: Prior Negative Reproductive	Racist microaggressions and explicit race- based discrimination	1
Healthcare Experience	Experiences with obesity and fat shaming	
Medical: Prior or	Gynecologic conditions (e.g., polyps and fibroids)	The second secon
Concurrent GYN Conditions	History of very heavy periods / abnormal uterine bleeding.	1
	Non Gyn comorbid health conditions or procedures	Ļ
Structural: Access to quality healthcare provider relationship Providers' responses are vague, reassuring, or otherwise minimize risk.		1
Epidemiological: Underlying Histologic Risk	Population rate of aggressive histologic subtypes.	1

Doll KM, Nguyen A, Alson JA. Gynecologic Oncology. 2022 Feb; 164(2):318-324

Appraisal Interval: Overlapping Vulnerability

Overlapping Vulnerability and Underlying Risk of EC Care Delay

Areas of Vulnerability	Contributor	Black Women Vulnerability	White women vulnerability	Native / Indigenous	
Experiential: Knowledge	Knowledge about menopause and the menopausal transition.	1	Ļ	people?	
	Endometrial Cancer knowledge	1	1		
Experiential: Prior Negative Reproductive	Racist microaggressions and explicit race- based discrimination	1		Trans, Queer, and Gender Non-Binary Individuals?	
Healthcare Experience	Experiences with obesity and fat shaming	1	1		
Medical: Prior or Concurrent GYN Conditions	Gynecologic conditions (e.g., polyps and fibroids)	1	Moderate		
	History of very heavy periods / abnormal uterine bleeding.	1	Ļ	Immigrants, refugees, and/or low English proficiency?	
	Non Gyn comorbid health conditions or procedures	Ļ	Moderate		
Structural: Access to quality healthcare provider relationship	Providers' responses are vague, reassuring, or otherwise minimize risk.	1	Moderate		
Epidemiological: Underlying Histologic Risk	Population rate of aggressive histologic subtypes.	1	I	And more	

Doll KM, Nguyen A, Alson JA. Gynecologic Oncology. 2022 Feb; 164(2):318-324

Doll KM, Khor S, Odem-Davis K, He H, Wolff E, Flum D, Ramsey S, Goff BA. AJOG. Dec 2018

Diagnostic Interval: Care Delivery Omissions

SEER-Medicare Study

EC Cases 2000-2011 (N=4,354 (W), 537 (B))

Identified symptoms (bleeding) and procedures (TVUS, biopsy, D&C) prior to diagnosis

Black women with aRR 1.12 – 1.74 for non-guideline $_{\rm o}$ adherent work up

Non-guideline pathways associated with **aOR 2.3-2.5** with Stage 3-4 disease





Influencing Factors on Diagnostic Interval among Women with EC



Black women had 27% longer time from bleeding to diagnosis.

Median days: 28 days (1 – 110)

This was **explained** by 1) bleeding classification and 2) lack of prompt biopsy, TVUS or D&C.

Overall **time was NOT related to stage at diagnosis**, as the time intervals were *relatively narrow*.

Diagnostic Interval: Provider Survey



How are Peri-menopausal Reproductive Symptoms Assessed by First Line Providers?

Demonstrated overall moderate (6/10) EC knowledge

Indicated **non-guideline adherent management choices** from **10 to up to 39%** in response to EC symptoms

Within guideline choices, preferred TVUS > biopsy



Provider Characteristics	N (%)
Fam Med, IM, or EM	252 (47.5%)
No University Affiliation	350 (73%)
NP (vs MD)	195 (37%)

Sage L...Doll, KM. J Womens Health (Larchmt). 2023 Oct;32(10):1104-1110

JAMA Oncology | Original Investigation

Estimated Performance of Transvaginal Ultrasonography for Evaluation of Postmenopausal Bleeding in a Simulated Cohort of Black and White Women in the US Guidelines

Kemi M. Doll, MD, MS; Sarah S. Romano, MPH; Erica E. Marsh, MD; Whitney R. Robinson, PhD

	Black	White	Absolute Difference	Relative Black : White
Sensitivity	47.5%	87.9%	40.4%	84% more sensitive test for White women
NPV	91.7%	97.0%	5.3%	2-fold increase in number of false negative results
AUC	0.57	0.73		Overall nearly 30% better performance among White women

Table. **Race Comparison** of Performance of TVUS ET 4MM thresholds for identifying endometrial cancer among a simulated cohort with postmenopausal bleeding

Study: Quality of the Guidelines

Guidelines that emphasize TVUS are based on a paradigm of a low-risk population, high accuracy of the test, and low consequences in the setting of a false negative.

None of these assumptions apply to U.S. Black women at risk for EC.

Our clinical algorithm has **built in racial inequity** in effectiveness which likely contributes to delayed diagnoses.

Doll, Romano, Marsh & Robinson. JAMA Oncology. July 2021;7(8):1158-1165



Robert Wood Johnson Foundation AMFDP 2018 - 2021



Application of The Andersen Model of Total Patient Delay

Overlapping Vulnerability and Underlying Risk of EC Care Delay

Overlapping Vulnerability + Underlying Risk = EC Care Delay





https://ecanawomen.org

Originally Funded by PCORI, UW ITHS, generous donors --> Now Independent 501©3 Non-profit



Adrienne Moore, RT, Me-BA

RESEARCHJW Medicine
GRACE Center 2024 At A Glance: Projects

Current Projects (Leading)	Current Projects (Collaborating)	Mentored Work
The SISTER Study (Social Interventions for Support in Treatment of Endometrial Cancer and Recurrence) – DOLL	Racial Differences in Hysterectomy: A Multilevel Investigation – ROBINSON, Duke (R01)	Unblinding the Disparities Within: Evaluation of Gynecologic Cancer Clinical Trials using a Health Equity Lens - OLULORO
GUIDE-EC : Guidelines for Ultrasound in early Detection of Endometrial Cancer - DOLL	ITHS Community Engagement Core: Preclinical Research Engagement – KO, UW (U54)	Low English Proficiency (LEP) and Delays in Gynecologic Oncology care - GROSS
Dissemination Tool of Biopsy-First Early Detection of EC: GUIDES BY US - DOLL	TP53 in Endometrial Cancer Development and Racial Disparities – RISQUES & DOLL (CCSG Pilot)	Improving Labor and Birth experiences of Bisexual Women of Color - WILLIAMS
Designing Novel Mechanisms for Acceptability of Blood and Tissue Based Research among Black women with high-risk endometrial cancer (ACTS) - DOLL	Nultilevel Determinants of Racial	JONES
	Disparities in Receipt of Guideline- concordant Endometrial Cancer	Under Review
	Treatment (R01, PI: Felix, OHSU)	Observing and Understanding Racial Hypervigilance on the SISTER Study (OUR
ROSES : Roles of Social Change in Engagement Science- DOLL	The Carolina Endometrial Cancer Study	SISTER) NCI R01 Feb 2024 / Nov 2024
	(Collab, PI: Olshan/Nichols)	The SISTER Extension Study – PCORI LTFU June 2024

<u>**G**</u>uidelines for <u>U</u>ltrasound <u>In the</u> <u>**D**</u>etection of <u>**E**</u>arly <u>**E**</u>ndometrial</u> <u>**C**ancer (*GUIDE-EC Study*)</u>



Goal: To inform guideline change through development of a riskbased approach to evaluating symptomatic Black women via 3,500 Black women cohort.





Kuni Foundation Discovery Award; 2021-2024

Whitney Robinson, PhD Eric Social Epidemiology Repro-Duke University

Erica Marsh, MD MSCI Reproductive Endocrinology U of Michigan

Data collection



CDW-H: Carolina Data Warehouse for Health (search query engine for EPIC)



ABSTRACTION INSTRUMENT: OVERVIEW



Abstraction Process & Quality Control

- 4 professionally trained abstractors with > 20+ years combined experience
- 30 page Abstraction Protocol with live updates/auditing
- 3 Levels of QC:
 - 5% records chosen at random for double abstraction
 - Computer based comparison of all entries
 - Discrepancies flagged and categorized (ie. Typo vs. error vs difference in interpretation)
 - Study team and/or clinician review to resolve
 - Abstractor-generated questions \rightarrow PI + Study team review
 - Triggers direct clinical record by clinician if needed
- Included direct Epic records, scanned records from OSHs, and telephone and nursing notes

Example Abstraction Flowchart tool





Julianna Alson, MPH SENIOR PROJECT MANAGER



Patrice Williams, B.S

I W Medicine

Data Abstraction: August 2021 – August 2022

eFigure 1. Flowchart of inclusion and exclusion of patient cases from the GUIDE-EC full sample.





JAMA Oncology | Original Investigation

Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals

Kemi M. Doll, MD, MSCR; Mindy Pike, PhD; Julianna Alson, MPH; Patrice Williams, BA; Erin Carey, MD, MSCR; Til Stürmer, MD, PhD; Mollie Wood, PhD, MPH; Erica E. Marsh, MD, MSCI; Ronit Katz, DPhil; Whitney R. Robinson, PhD



	0
	1
N	
2	

Julianna Alson, MPI Patrice Williams, B.S. Table 3. Sensitivity, Specificity, and False-Negative Probability of Endometrial Cancer by Endometrial Thickness Thresholds in the 1494 Participants No. of patients Endometrial thickness **Endometrial cancer** No endometrial cancer False-negative probability, threshold, mm (n = 210)(n = 1284)Sensitivity, % (95% CI) Specificity, % (95% CI) % (95% CI) Threshold: 3 mm <3 8 108 3.8 (1.7-7.4) 96.2 (92.6-98.3) 8.4 (7.0-10.1) ≥3 202 1176 Threshold: 4 mm <4 20 208 16.2 (14.2-18.3) 9.5 (5.9-14.3) 90.5 (85.7-94.1) 190 1076 ≥4 Threshold: 5 mm 24 331 <5 11.4 (7.5-16.5) 88.6 (83.5-92.5) 25.8 (23.4-28.3) 186 953 ≥5

Mindy Pike, PhD



JAMA Oncology | Original Investigation

Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals

Kemi M. Doll, MD, MSCR; Mindy Pike, PhD; Julianna Alson, MPH; Patrice Williams, BA; Erin Carey, MD, MSCR; Til Stürmer, MD, PhD; Mollie Wood, PhD, MPH; Erica E. Marsh, MD, MSCI; Ronit Katz, DPhil; Whitney R. Robinson, PhD

> Figure. False-Negative Probability of Endometrial Thickness Measurement for Endometrial Cancer Diagnostic Triage Among Black Individuals



Patrice Williams, B.S.



Julianna Alson, MPH

Mindy Pike, PhD

CONCLUSION AND RELEVANCE These findings suggest that the transvaginal ultrasonography triage strategy is not reliable among Black adults at risk for EC. In the presence of postmenopausal bleeding, tissue sampling is strongly recommended.

Aim 2 Paper in Progress: Identifying people at high risk for suboptimal diagnostic pathway.





JOIN US IN A DIALOGUE TO IMPROVE HEALTH CARE FOR BLACK WOMEN!

This is a dialogue about your gynecologic healthcare experiences as Black Women. We can improve healthcare and survival among Black women. Join us for a group discussion.

WHY PARTICIPATE

Endometrial (uterine) cancer is the most common gynecologic cancer in the United States - more common than cervical and ovarian cancer.

Black women are almost twice as likely to die from endometrial cancer compared with white women in the U.S. This is partly because Black women are more likely to be diagnosed later. Earlier diagnosis may lead to better outcomes!

TO PARTICIPATE YOU MUST BE A:

Black or African-American Woman with one of the following criteria:



*Concerning bleeding can include heavy periods lasting more than 7 days, irregularly timed cycles, spotting in-between periods, requiring transfusions or medications to manage your menstrual cycle

HOW DO I PARTICIPATE?

Visit the link below to take a survey to see if you are eligible, and feel free to share!



Assistance with the survey is available, follow instructions at the link. The focus groups will take place in Durham & Charlotte in June 2023. If you're selected, we will contact you with the time and location. Focus group participants will be provided with a \$100 gift card.

FOCUS GROUPS ON BIOPSY & US EXPERIENCES



Durham Arts Council Age 35 – 49 10 participants

Virtual Age 50+ 7 participants



Julianna Alson, MPH

Patrice Williams, B.S.



Pauline's Tea Room - Charlotte Age 50+ 8 Participants

GUIDE EC FOCUS GROUPS - RESULTS





Components and prerequisites of a successful risk-based provider discussion about biopsy *Patient is <u>empowered</u> to make a risk-informed choice that will maximize chances of early EC detection

Acknowledgment of medical racism	Race concordant medical care	Ample opportunities to ask questions		
Personalized care re	ecommendations Description pain/	h of the full range of possible discomfort experiences		
Detailed, lay-oriented health education				
Racial disparities in EC and ultrasound utility	Physical risks of waiting for biopsy choosing	pnal rs of biopsy Procedure mechanisms and logistics		

GUIDE EC PROVIDER INTERVIEWS

Semi-structured interview with 12 providers (OBGYN, IM, FAM MED, ED)

Barriers/facilitators to biopsy-first

Perceptions of Racial Disparities in outcomes for EC

Uncertainty in specifics of guidelines

Skepticism in ability to tailor diagnostic evaluation

Apathy/disinterest in addressing this issue

Facilitators

- Clinical decision-making support
- Education/dissemination of new recommendations
- Increased proportion of providers performing EMB

Barriers

- Acceptability of same-day biopsy to patients
- Pain management
- Lack of provider ability to perform EMB
- System/resource barriers



Maya Gross, MD MPH



Minerva Orellana, PhD



GUIDElineS for endometrial cancer detection: **B**iops**Y** vs. **U**Itra**S**ound (*GUIDES BY US*)

Goal: Develop & disseminate multi-media toolkit and interactive decision aid for Black women and gender expansive individuals with symptoms of EC



Define risk factors for NON-DIAGNOSTIC ultrasound results.

Convene focus groups to elicit barriers and facilitators to 'biopsy-first' approach: Black women + Gender expansive individuals

Create and test a public facing educational toolkit



Congratulations to Kemi M. Doll, MD, MCSR, a recipient of a 2023 Victoria's Secret Global Fund for Women's Cancers Rising Innovator Research Grant, in Partnership with Pelotonia & AACR. Her work can improve endometrial cancer diagnosis in Black women. @VictoriasSecret @Pelotonia



12:02 PM · Mar 30, 2023 · 22.7K Views

AACR Victoria's Secret Global Fund; 2023 - 2026

GUIDES BY US: DEVELOPMENT OF A MIXED MEDIA TOOLKIT



GE FOCUS GROUP AMERICAN PUBLIC HEALTH ASSOCIATION ABSTRACT - <u>ACCEPTED</u>



Minerva Orellana, PhD

APHA 2024 Annual Meeting

Speakers' Corner

Presentation Details

Please note: All live events are scheduled for Eastern Time

Abstract Title: Incorporating black gender expansive voices in endometrial cancer public health messaging Abstract ID: 549032 Part of Session: 5079.0: Transgender and Gender Diverse People's Health Date/Time: Wednesday, October 30, 2024: 10:30 a.m.-12:00 p.m. in Duluth Room Session Type: Oral Program: LGBTQ Health Caucus





UW IVIEDICINE

'Narrowing', or *Eliminating* the Mortality Gap?

Not all endometrial cancer is created equal. **Over half** of Black women diagnosed with EC have **high-risk histology** type.



'Narrowing', or *Eliminating* the Mortality Gap?

Survival is more than access to care. Black women have lower survival on clinical trials and with guidelineconcordant treatment Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma on GOG/NRG Clinical Trials



Maxwell et al. Cancer. 2006

UW Medicine

The Ecosocial Theory of Disease Distribution

Endometrial Cancer US Mortality Rates by Race/Ethnicity 1999-2018



Social Isolation & Endometrial Cancer



Lutgendorf SK, et al. JCO. 2012;30(23)

Social isolation is lethal in cancer treatment.



Note: Highlight indicates measured by The SISTER Study

Adapted from Kroenke CH *et al*. A conceptual model of social networks and mechanisms of cancer mortality, and potential strategies to improve survival. *Transl Behav Med.* 2018;8(4):629-642.



13 SISTER Study sites



Beza Tadess, MPH

Lisa Johnson PhD

UW Medicine

SISTER Trial Enrollment over Time



Lesson: Do NOT try to launch a (non-COVID) multi-site randomized trial during a pandemic.

SISTER enrollments









SISTER is more than a trial...It's a community



SISTER is a Hybrid Effectiveness-Implementation Trial Type I



The SISTER Study: A Seed for Future Discovery & Survival





experimenters Experimenters Frontline Responders Eduity Justice Solidarity

Visionaries

2 @dviyer

@BldingMovement

Builders

Roles of Social Change in Engagement Science (ROSES Study)

> **Goal:** Create reproduceable structures to guide research partnerships in creating a balance of needed perspectives and supporting long-term successful community engagement



FIG1. Conceptual Model of Social Change Roles in Engagement. Social change roles are different perspectives that harmonize to produce sustained impact and change in social movements. Each role may experience engagement quality differently based on differing perceived importance of underlying engagement constructs.



Leah Franklin, MPH



Patrice Williams, B.S



PCORI Science of Engagement #2022C2-28908;

Attribution: Deepa Iyer, Building Movement Project. SM. © 2018 Deepa Iyer.

All rights reserved. All prior licenses revoked.

Caregivers

Healers

@BuildingMovementProject

@deepaviyer

Disrupters

GOAL: CREATE A FRAMEWORK TO GUIDE OTHER TEAMS



Advisory Council for Translational Science (ACTS)

Goals:

To determine best **recruitment approaches** and data sharing practices that optimize acceptability and participation in biospecimen research among Black women with EC.

Recruit and convene an **Advisory Council** to oversee all translational research efforts.







Beza Tadess, MPH

Patrice Williams, R.



Objectives

1. Introduce The GRACE Center mission, vision, and values.

2. Review GRACE Center research studies.

3. Discuss future horizons and collaboration opportunities.

The GRACE Center: 2023-24 Progress



The GRACE Center: Looking Ahead...



LEAD (7): SISTER, Black Enrollment on Trials, ACTS, ROSES, GUIDES BY US, **OUR** SISTER (R01), SISTER Extension Study (PCORI)

RESEARCH

COLLABORATE (4): CHC, TP53 in EC, EC Treatment Disparities (R01), Carolina Endometrial Cancer Study, New AUB mPI R01, GUIDE-EC based grants/papers

CONSULT: ITHS Preclinical Engagement, STRIVE

OUR SISTER (R01)

- Structural: 5 years funding for SISTER Team.
 Building biorepository for future EC questions.
- Research: Advancing study of embodiment of racism and concept of racial hypervigilance

SISTER Extension Study (PCORI)

- Structural: 5 years funding for SISTER Team.
 Continued database of survey, treatment, and interview data for future studies.
- Research: understand social support 'cliff', long term QoL issues for survivors, how new treatment landscape is affecting survival



Conceptual Model of Racism as a Fundamental Cause That Contributes to Poor Disease Outcomes


On the horizon: Observing and Understanding Racial Hypervigilance on the SISTER Study (OUR SISTER)

- Goal: Understanding how exposure to structural racism influences individual hypervigilance (stress) and EC poor prognostic tumor features.
- Goal: Build a biorepository of **tissue**, **blood**, **and other biospecimens** from the SISTER cohort for this study and future research.





GUIDE EC: Opportunity for ANCILLARY STUDIES

- 3,500 Black individuals who underwent hysterectomy over 6+ years
- 10 hospitals + 100s outpatient clinics
- 1400 possible data points per case entry
- Detailed gynecologic symptoms up to 24 months prior to surgery
- General medical & social history including mental health
- Detailed ultrasound quality and measurement data
 - fibroid location, fibroid size
- MRI, D&Cs

Next Step: Develop data access and proposal process

The GRACE Center: Narrative Shifts...



Mother Jones

The Moment for Mother Jones
Dollar-for-dollar matching gift!

POLITICS ENVIRONMENT CRIME AND JUSTICE FOOD MEDIA INVESTIGATIONS PHOTOS MAGAZINE PODCAS

POLITICS OCTOBER 21, 2019

Why Are More Black Women Dying From the Most Common Reproductive Cancer?

There are a couple theories.

Bio

y

-





1 25

gynecologic cancer awareness month

Every gynecologist should brief their patients on uterine cancer symptoms both pre- and post-menopause."

– Rebecca L.



 Aminatou Sow ② @aminatou - Jan 24

 Hey Twitter! Exactly a year ago I had a total abdominal hysterectomy with a bilateral salpingo-oophorectomy. That means a removal of the uterus, cervix, fallopian tubes, and ovaries. The whole sink!

 20
 tl 181
 1.8K

 Aminatou Sow ③ @aminatou - Jan 24

 The good news: I don't have endometrial cancer right now!

 The meh news: Menopause is a beast! Being a cancer survivor is hard in its own ways.

♀ 1↓11 ♡838 止

- Aminatou Sow @ @aminatou Jan 24 Your chances of surviving endometrial cancer might depend on your race unfortunately. This is the same cancer that took Gwen Ifill away from us. Black women have a 55-percent higher mortality rate after diagnosis than other groups of women Q 3 11 62 2405 1
- Aminatou Sow @ @aminatou Jan 24 One of the few people in the country studying this is Dr @KemiDoll. Her research focuses on disparities in uterine capper (endometrial capper is
- research focuses on disparities in uterine cancer [endometrial cancer is the most common type of uterine cancer]



One Type Of Cancer Is Killing Black Women At Record-High Rates

White women are less likely to die from the same condition.



GOODMORNINGAMERICA.COM

Studies show endometrial cancer is more aggressive for Black women Dr. Kemi Doll is committed to eliminating the racial mortality gap in endometrial cancer thro...

Awareness is rising...

RMAL VAGINAL BLEEDING? SEE A DOCTOR





Endometrial cancer is a cancer of the womb that disproportionately affects Black women. In fact, Black women are nearly twice as likely to die from endometrial cancer than other women. And it can't usually be detected by a routine Pap smear, so knowing what to look for can be key to getting treated. *Red Dab? Red Flag* aims to make Black

women aware that if they experience any unusual spotting or a red dab of blood, it could be a sign of endometrial cancer and to talk to their doctor, sooner.



September Gynecologic Cancer Awareness Month 2022



Watch Dr Doll's Message to Black Women

Watch Shawn's Powerful Patient Story

www.RedDabRedFlag.com



JAMA Oncology | Original Investigation

Endometrial Thickness as Diagnostic Triage for Endometrial Cancer **Among Black Individuals**

Kemi M. Doll, MD, MSCR; Mindy Pike, PhD; Julianna Alson, MPH; Patrice Williams, BA; Erin Carey, MD, MSCR; Til Stürmer, MD, PhD; Mollie Wood, PhD, MPH; Erica E. Marsh, MD, MSCI; Ronit Katz, DPhil;

Whitney R. Robinson, PhD







WOMEN'S HEALTH

Common endometrial cancer test is less effective for Black women, research shows

New study suggests the test may be missing cancers among Black patients more often.

CONCLUSION AND RELEVANCE These findings suggest that the transvaginal ul triage strategy is not reliable among Black adults at risk for EC. In the presend postmenopausal bleeding, tissue sampling is strongly recommended



Ultrasounds may not find endometrial cancer in lack patients

cer is the most common type of gynecological cancer in the Unite is. It is becoming increasingly prevalent, especially among Black people, who are re likely to receive a late-stage diagnosis. A study led by UW researchers and ed in JAMA Oncology found that a common diagnostic strategy can fail to catc dometrial cancer 4% to 11% of the time in Black patients

With more money and more attention pouring into EC, it's critical we have **INFORMED** and **ENGAGED** voices in the public sphere.

Kemi Do

Ultrasound May Be Unreliable in Spotting Endometrial Cancer in Black Women







Health A to Z News For Medical Professionals Video Content Licensing Custom Content About Spanish

Chemical Hair Relaxers and EC

 Use > 4 times in 12 mo prior to study enrollment → HR 2.55

Use of Straighteners and Other Hair Products and Incident Uterine Cancer

Che-Jung Chang, PhD ⁽¹⁾, Katie M. O'Brien, PhD,¹ Alexander P. Keil, PhD,² Symielle A. Gaston, PhD,¹ Chandra L. Jackson, PhD,^{1,3} Dale P. Sandler, PhD,¹ Alexandra J. White, PhD, MSPH ⁽¹⁾,*



uterine cancer

Several women diagnosed with uterine cancer are now suing L'Oreal and other cosmetic companies after a recent study tied the illness to chemical hair straightening products. Dr. Kemi Doll joined Amna Nawaz to discuss the study and the concerns it has raised.

PBS News Hour

Hair relaxer use and risk of uterine cancer in the Black Women's Health Study

Kimberly A. Bertrand ^{a, b, *, 1}, Lauren Delp ^a, Patricia F. Coogan ^a, Yvette C. Cozier ^{a, c}, Yolanda M. Lenzy ^{d, e}, Lynn Rosenberg ^a, Julie R. Palmer ^{a, b}

Postmenopausal women:

- HR 1.6 for moderate and heavy use

AACHR American Association for Cancer Research

- HR 1.71 for > 20 years of use
- HR 1.85 for >5-6 times per year

How does our emphasis on obesity cloud our innovation in exploring environmental risk factors in North America, among Black women, and variation by other marginalized status?

AACR SPECIAL CONFERENCE IN CANCER RESEARCH: ENDOMETRIAL CANCER: TRANSFORMING CARE THROUGH SCIENCE

Early Stage At Diagnosis

GUIDES projects follow up analyses Multi-level Intervention Execution **GUIDES By US - Dissemination**

Embodiment and Outcomes

Racism, Deprivation, and EC Histology (OUR SISTER) Social Support and Survival (The SISTER Study)

Comm Engagement & Trial Methods

(ACTS)

Goal: Close the Gap



Roles of Social Change in Engagement Science (ROSES)

Lesson: Start anywhere, just be sure to start.

ORIGINAL STUDY Detection of Gynecologic Cancers in Indigent Women in an Urban Inner-City Hospital Kemi M, Doll, MD.*† Roman Puliaev, MD.* Julie Chor, MD, MPH.*† Alicia Roston, MPH.* Urjeet A. Patel, MD, *† and Ashlesha Patel, MD, MPH*† Objective: Access to care is a major concern for impoverished urban communities in the United States, whereas early detection of gynecologic malignancies significantly influences ultimate survival. Our goal was to compare the stage at detection of common gynecologic cancers at an urban county hospital with national estimates, and to describe the demographic and socioeconomic characteristics of this population. Methods: All new patients presenting to the John H. Stroger, Jr. Hospital of Cook County gynecologic oncology clinic from January 1, 2008, to December 31, 2009, were reviewed under an institutional review board-approved protocol. Patients receiving primary treatment at the institution during these dates were included for analysis. We used γ^2 tests to compare the institution's stage distributions to national estimates. Results: Two hundred nineteen patients met inclusion criteria over the 2-year study period. Racial and ethnic minorities represented 72.5% of the population. Of the 219 patients, 56.1% (123/219) were uninsured and 37.9% (83/219) were covered by Medicaid or Medicare. We identified 97 (43.9%) cervical, 95 (43%) uterine, and 29 (13.1%) ovarian cancers, including 2 synchronous primaries. Compared to the National Cancer Data Base, women with uterine cancer at our institution were significantly more likely to present with later-stage disease (P < 0.05), whereas cervical cancer and ovarian cancer stage distributions did not differ significantly. Conclusions: Compared to national trends, women with uterine cancer presenting to an urban tertiary care public hospital have significantly more advanced disease, whereas those with cervical cancer do not. Nationally funded cervical cancer screening is successful but does not address all barriers to accessing gynecologic cancer care. Promotion of public education of endometrial cancer symptoms may be a vital need to impoverished communities with limited access to care. Key Words: Uterine cancer, Cervix cancer, Minority health, Early detection of cancer Received April 9, 2012, and in revised form May 9, 2012. Accepted for publication May 14, 2012. (Int J Gynecol Cancer 2012;22: 1113-1117) My resident research project, submitted April 9 2012! The epidemiology of gynecologic reported. Both cervical and utering *John H. Stroger, Jr. Hospital of Cook County; and †Northwestern to early detection and often present w University Feinberg School of Medicine, Chicago, IL. This is reflected in national databases Address correspondence and reprint requests to Kemi M. Doll. MD. patients with stage I disease is more Department of Obstetrics and Gynecology, Northwestern cancer and nearly 70% for uterine cancer. Prognosis is ex University, 250 E Superior St, Suite 5-2177. cellent for the patients who are often cured by surgery and E-mail: kemidoll@gmail.com. avoid lengthy and costly adjuvant therapies that have signif-The authors declare no conflicts of interest Copyright © 2012 by IGCS and ESGO icant impact on quality of life.2 ISSN: 1048-891X Disparities exist, however, in cancer presentation, treat-DOI: 10.1097/IGC.0b013e31825f7fa0 ment, and survival. It is known that significant cancer care International Journal of Gynecological Cancer • Volume 22, Number 7, September 2012 1113

"...Nationally funded cervical cancer screening is successful but does not address all barriers of gynecologic cancer care. *Promotion of public education of endometrial cancer symptoms may be a vital need to impoverished communities with limited access to care.*"



ACKNOWLEDGEMENTS

Funding Support: UW Dept of OBGYN

Robert Wood Johnson Foundation

National Institutes for Minority Health and Health Disparitie

National Comprehensive Cancer Network Foundation

Patient Centered Outcomes Research Institute (PCORI)

UW Institute for Translational Health Science

Fred Hutchinson Cancer Research Center

Wayne J. Kuni Foundation

Merck, Inc.

Generous donors

















THANK YOU





@KemiDoll @guidesbyus

https://ecanawomen.org

www.gracecenteruw.com